Wall Street Analyst Actions To Watch: KeyCorp (KEY), BioPharmX Corporation (BPMX)

KeyCorp (NYSE:KEY) was less active in the last trading session as around 6.35 million shares exchanged hands on Wall Street, representing a decrease from its normal capacity of 9.18 million shares. A 1.61% change after the initial price of $19.47, sent the closing price to $19.85.

KeyCorp (KEY) Analyst Opinion

KeyCorp has a consensus outperform rating from 26 Wall Street analysts, and the number of shares currently sold short amount to at least 1.62% of shares outstanding. The stock spiked 0.53% last month and is down -1.56 this year. Wall Street is only getting more bullish on the stock, with 20 of analysts who cover KEY having a buy-equivalent rating. Analysts have placed a $23.42 price target on KeyCorp, suggesting a 17.98% gain from recent close. It’s currently trading about -11.36% below its 52-week high.

KeyCorp Earnings Surprise

KeyCorp (KEY) failed to surprise the stock market in its last reported earnings when it earned $0.38 a piece versus the consensus-estimated $0.38. Its revenue totaled $1.56 billion down -2.32% from the previous quarter.

KeyCorp (NYSE:KEY) Intraday View

This stock (KEY) is ahead of its 52-week low with 21.96%. Its last month’s stock price volatility remained 2.44% which for the week stands at 2.1%. The share price has moved backward from its 20 days moving average, trading at a distance of -2% and stays -1.35% away from its 50 days moving average. Over the last five days, shares have faced -1.27% losses and now is up 0.19% since hitting its 200-day moving average of $20.42. KeyCorp (KEY) has made its way to a 12-month gain of 5.95%.

Turning to BioPharmX Corporation (NYSE:BPMX), its shares were trading at $0.22 a retreat of $0, on the trading floor. The stock, after opening at $0.2318, touched a high of $0.235 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. BioPharmX Corporation has 0 buy ratings, 0 holds and 0 sells even after the stock tumbled -55.72% from its high of $0.50 to a $40.77 million market value through last close.

BioPharmX Corporation (BPMX) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 2 to 2 during a month. Analysts set a 12-month price target of $1.05 a share. The target implies a 377.27% spike from where the shares are currently trading. Also, the current price highlights a discount of 581.82% to analysts’ high consensus price target.

BioPharmX Corporation (NYSE:BPMX) Intraday Trading

The counter witnessed a trading volume of 1.73 million shares versus an average volume of 4.81 million shares during last trading session. Its last month’s stock price volatility remained 9.08% which for the week approaches 7.3%. The lowest price the stock reached in the last trading day was $0.22 and compares with the $0.10 52-week low. The stock recovered 121.4% since its low point and has performed 100.91% year-to-date.